





THE ROLE OF GENERIC MEDICINES IN SUSTAINING HEALTHCARE SYSTEMS: A EUROPEAN PERSPECTIVE

HEALTHCARE BUDGET CHALLENGES

AGEING POPULATION





HYPERTENSION

129 Million

+50%

ASTHMA/COPD

191 Million patients >65 years



2050

GENERIC MEDICINES CONTRIBUTION

ECONOMIC VALUE



56% OF VOLUME SUPPLIED BY GENERIC MEDICINES



75% OF GENERIC MEDICINES ARE MANUFACTURED IN EUROPE



-€100BN

WITHOUT GENERIC MEDICINES, GOVERNMENTS WOULD HAVE HAD TO PAY AN ADDITIONAL €100BN IN 2014



INCREASED INCIDENCE OF CHRONIC DISEASES











GASTRO-INTESTINAL DISEASE

INCREASED PATIENT ACCESS




TWICE AS MANY PATIENTS TREATED



NO IMPACT ON BUDGET

HIGH COST OF NEW MEDICINES



BENEFITS FOR COUNTRIES





IMPACT

ON

ACCESS



IMPACT

ON





UNDERSERVED GROUPS MORE PATIENTS TREATED

INCREASED ACCESS FOR





BETTER VALUE FOR TREATMENT

FOR SAME BUDGET